Nanyang Tianhua Biotechnology Group Co., Ltd. is a large-scale high-tech pharmaceutical company integrating product R & D, production, and sales. It has more than ten branches, including 3 GMP factories: Nanyang Tianhua Pharmaceutical Co., Ltd., Nanyang Libang Pharmaceutical Co., Ltd., and Henan Quanyu Pharmaceutical Co., Ltd. The group’s business involves many fields such as human API, herbal liquid, Chinese traditional oral medicines, veterinary API and preparations.
Previously Tianhua Group focused on domestic business for many years, and its international business was fully launched in 2020; In 2020, the first API Operation Center was established in Beijing; In 2022, Premix and Animal Drug Operation Center was established in Zhengzhou;
In 2024, Keyland Pharmaceutical, based in Hangzhou, became the group’s main export business center.
At present, the group’s overseas business has covered more than 20 countries and regions, including Asia, South America, Africa, and Europe.